|
1
|
Wise-Draper TM, Draper DJ, Gutkind JS,
Molinolo AA, Wikenheiser-Brokamp KA and Wells SI: Future directions
and treatment strategies for head and neck squamous cell
carcinomas. Transl Res. 160:167–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee JH, Song JH, Lee SN, Kang JH, Kim MS,
Sun DI and Kim YS: Adjuvant postoperative radiotherapy with or
without chemotherapy for locally advanced squamous cell carcinoma
of the head and neck: The importance of patient selection for the
postoperative chemoradiotherapy. Cancer Res Treat. 45:31–39. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Argiris A, Karamouzis MV, Raben D and
Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thariat J, Milas L and Ang KK: Integrating
radiotherapy with epidermal growth factor receptor antagonists and
other molecular therapeutics for the treatment of head and neck
cancer. Int J Radiat Oncol Biol Phys. 69:974–984. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kupfer GM: Fanconi anemia: A signal
transduction and DNA repair pathway. Yale J Biol Med. 86:491–497.
2013.PubMed/NCBI
|
|
6
|
Kutler DI, Auerbach AD, Satagopan J,
Giampietro PF, Batish SD, Huvos AG, Goberdhan A, Shah JP and Singh
B: High incidence of head and neck squamous cell carcinoma in
patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg.
129:106–112. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Virts EL, Jankowska A, Mackay C, Glaas MF,
Wiek C, Kelich SL, Lottmann N, Kennedy FM, Marchal C, Lehnert E, et
al: AluY-mediated germline deletion, duplication and somatic stem
cell reversion in UBE2T defines a new subtype of Fanconi anemia.
Hum Mol Genet. 24:5093–5108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rickman KA, Lach FP, Abhyankar A, Donovan
FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O,
Chandrasekharappa SC, et al: Deficiency of UBE2T, the E2 ubiquitin
ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T
subtype of Fanconi anemia. Cell Rep. 12:35–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kee Y and D'Andrea AD: Molecular
pathogenesis and clinical management of Fanconi anemia. J Clin
Invest. 122:3799–3806. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim H and D'Andrea AD: Regulation of DNA
cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev.
26:1393–1408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jo U and Kim H: Exploiting the Fanconi
anemia pathway for targeted anti-cancer therapy. Mol Cells.
38:669–676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang LC and Gautier J: The Fanconi anemia
pathway and ICL repair: Implications for cancer therapy. Crit Rev
Biochem Mol Biol. 45:424–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burkitt K and Ljungman M: Phenylbutyrate
interferes with the Fanconi anemia and BRCA pathway and sensitizes
head and neck cancer cells to cisplatin. Mol Cancer. 7:242008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu J, Su F, Mukherjee S, Mori E, Hu B and
Asaithamby A: FANCD2 influences replication fork processes and
genome stability in response to clustered DSBs. Cell Cycle.
14:1809–1822. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burdak-Rothkamm S, Rothkamm K, McClelland
K, Al Rashid ST and Prise KM: BRCA1, FANCD2 and Chk1 are potential
molecular targets for the modulation of a radiation-induced DNA
damage response in bystander cells. Cancer Lett. 356(2 Pt B):
454–461. 2015. View Article : Google Scholar
|
|
16
|
Lyakhovich A and Surralles J: FANCD2
depletion sensitizes cancer cells repopulation ability in vitro.
Cancer Lett. 256:186–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jeong YK, Kim MS, Lee JY, Kim EH and Ha H:
Metformin radiosensitizes p53-deficient colorectal cancer cells
through induction of G2/M arrest and inhibition of DNA repair
proteins. PLoS One. 10:e01435962015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu J, Ge YY, Zhu HC, Yang X, Cai J, Zhang
C, Lu J, Zhan LL, Qin Q, Yang Y, et al: Fenofibrate increases
radiosensitivity in head and neck squamous cell carcinoma via
inducing G2/M arrest and apoptosis. Asian Pac J Cancer Prev.
15:6649–6655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duangmano S, Sae-Lim P, Suksamrarn A,
Patmasiriwat P and Domann FE: Cucurbitacin B causes increased
radiation sensitivity of human breast cancer cells via G2/M cell
cycle arrest. J Oncol. 2012:6016822012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ashimori N, Zeitlin BD, Zhang Z, Warner K,
Turkienicz IM, Spalding AC, Teknos TN, Wang S and Nör JE: TW-37, a
small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle
arrest and suppresses head and neck tumor angiogenesis. Mol Cancer
Ther. 8:893–903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taniguchi T, Garcia-Higuera I, Andreassen
PR, Gregory RC, Grompe M and D'Andrea AD: S-phase-specific
interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and
RAD51. Blood. 100:2414–2420. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Farnebo L, Jerhammar F, Ceder R, Grafström
RC, Vainikka L, Thunell L, Grénman R, Johansson AC and Roberg K:
Combining factors on protein and gene level to predict
radioresponse in head and neck cancer cell lines. J Oral Pathol
Med. 40:739–746. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Findley HW, Gu L, Yeager AM and Zhou M:
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with
p53 status and sensitivity to apoptosis in childhood acute
lymphoblastic leukemia. Blood. 89:2986–2993. 1997.PubMed/NCBI
|
|
24
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schon EA and Manfredi G: Neuronal
degeneration and mitochondrial dysfunction. J Clin Invest.
111:303–312. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Van Der Heijden MS, Brody JR and Kern SE:
Functional screen of the fanconi anemia pathway in cancer cells by
Fancd2 immunoblot. Cancer Biol Ther. 3:534–537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chun J, Joo EJ, Kang M and Kim YS:
Platycodin D induces anoikis and caspase-mediated apoptosis via p38
MAPK in AGS human gastric cancer cells. J Cell Biochem.
114:456–470. 2013. View Article : Google Scholar
|
|
29
|
Su JC, Lin KL, Chien CM, Lu CM, Chen YL,
Chang LS and Lin SR: Novel indoloquinoline derivative, IQDMA,
induces G(2)/M phase arrest and apoptosis in A549 cells through
JNK/p38 MAPK signaling activation. Life Sci. 85:505–516. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salim H, Akbar NS, Zong D, Vaculova AH,
Lewensohn R, Moshfegh A, Viktorsson K and Zhivotovsky B: miRNA-214
modulates radiotherapy response of non-small cell lung cancer cells
through regulation of p38MAPK, apoptosis and senescence. Br J
Cancer. 107:1361–1373. 2012. View Article : Google Scholar : PubMed/NCBI
|
